Immunogenicity of allogeneic mesenchymal stromal cells: What has been seen in vitro and in vivo?

Regenerative Medicine

Volumn 10, Issue 3, 2015, Pages 305-315

  Consentius, Christine ^a   Reinke, Petra ^a   Volk, Hans Dieter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

antigen presenting cells; direct indirect alloimmunity; immunogenicity; immunomodulation; major histocompatibility complex; mesenchymal stromal cells

Indexed keywords

ALLOANTIGEN;

ALLOIMMUNITY; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; CELL DIFFERENTIATION; CELL TRANSPLANTATION; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL MONITORING; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE FUNCTION; MESENCHYMAL STROMA CELL; MULTIPOTENT STEM CELL; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; SIGNAL TRANSDUCTION; ALLOGRAFT; ANIMAL; CLINICAL TRIAL (TOPIC); HISTOCOMPATIBILITY; IMMUNOLOGY; MESENCHYMAL STEM CELL TRANSPLANTATION;

ALLOGRAFTS; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOMODULATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; TRANSPLANTATION IMMUNOLOGY;

EID: 84930003573     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.15.14     Document Type: Review

References (82)

1. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 284(5411), 143-147 (1999).
2. Spaggiari GM, Moretta L. Cellular and molecular interactions of mesenchymal stem cells in innate immunity. Immunol. Cell Biol. 91(1), 27-31 (2013).
3. Bernardo ME, Pagliara D, Locatelli F. Mesenchymal stromal cell therapy: a revolution in Regenerative Medicine? Bone Marrow Transplant. 47(2), 164-171 (2012).
4. Bura A, Planat-Benard V, Bourin P et al. Phase I trial: the use of autologous cultured adipose-derived stroma/stem cells to treat patients with non-revascularizable critical limb ischemia. Cytotherapy 16(2), 245-257 (2014).
5. Prather WR, Toren A, Meiron M. Placental-derived and expanded mesenchymal stromal cells (PLX-I) to enhance the engraftment of hematopoietic stem cells derived from umbilical cord blood. Expert Opin. Biol. Ther. 8(8), 1241-1250 (2008).
6. Roy R, Brodarac A, Kukucka M et al. Cardioprotection by placenta-derived stromal cells in a murine myocardial infarction model. J. Surg. Res. 185(1), 70-83 (2013).
7. Yi T, Song SU. Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications. Arch. Pharm. Res. 35(2), 213-221 (2012).
8. Prather WR, Toren A, Meiron M, Ofir R, Tschope C, Horwitz EM. The role of placental-derived adherent stromal cell (PLX-PAD) in the treatment of critical limb ischemia. Cytotherapy 11(4), 427-434 (2009).
9. Ramot Y, Meiron M, Toren A, Steiner M, Nyska A. Safety and biodistribution profile of placental-derived mesenchymal stromal cells (PLX-PAD) following intramuscular delivery. Toxicol. Pathol. 37(5), 606-616 (2009).
10. Barbash IM, Chouraqui P, Baron J et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation 108(7), 863-868 (2003).
11. Chiesa S, Morbelli S, Morando S et al. Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. Proc. Natl Acad. Sci. USA 108(42), 17384-17389 (2011).
12. Von Bahr L, Batsis I, Moll G et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-Term engraftment and no ectopic tissue formation. Stem Cells 30(7), 1575-1578 (2012).
13. Fouillard L, Bensidhoum M, Bories D et al. Engraftment of allogeneic mesenchymal stem cells in the bone marrow of a patient with severe idiopathic aplastic anemia improves stroma. Leukemia 17(2), 474-476 (2003).
14. Neef K, Choi YH, Weichel A et al. The influence of cardiovascular risk factors on bone marrow mesenchymal stromal cell fitness. Cytotherapy 14(6), 670-678 (2012).
15. Stamm C, Nasseri B, Drews T, Hetzer R. Cardiac cell therapy: a realistic concept for elderly patients? Exp. Gerontol. 43(7), 679-690 (2008).
16. Wang D, Zhang H, Liang J et al. Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. Cell Transplant. 22(12), 2267-2277 (2013).
17. Le Blanc K, Samuelsson H, Gustafsson B et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 21(8), 1733-1738 (2007).
18. Seifert M, Stolk M, Polenz D, Volk HD. Detrimental effects of rat mesenchymal stromal cell pre-Treatment in a model of acute kidney rejection. Front. Immunol. 3, 202 (2012).
19. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 108(6), 2114-2120 (2006).
20. Deuse T, Stubbendorff M, Tang-Quan K et al. Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells. Cell Transplant. 20(5), 655-667 (2011).
21. Oh W, Kim DS, Yang YS, Lee JK. Immunological properties of umbilical cord blood-derived mesenchymal stromal cells. Cell Immunol. 251(2), 116-123 (2008).
22. Chinnadurai R, Copland IB, Patel SR, Galipeau J. IDOindependent suppression of T cell effector function by IFN-gamma-licensed human mesenchymal stromal cells. J. Immunol. 192(4), 1491-1501 (2014).
23. Francois M, Romieu-Mourez R, Stock-Martineau S, Boivin MN, Bramson JL, Galipeau J. Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties. Blood 114(13), 2632-2638 (2009).
24. Majumdar MK, Keane-Moore M, Buyaner D et al. Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J. Biomed. Sci. 10(2), 228-241 (2003).
25. Chan JL, Tang KC, Patel AP et al. Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Blood 107(12), 4817-4824 (2006).
26. Sivanathan KN, Gronthos S, Rojas-Canales D, Thierry B, Coates PT. Interferon-gamma modification of mesenchymal stem cells: implications of autologous and allogeneic mesenchymal stem cell therapy in allotransplantation. Stem Cell Rev. 10(3), 351-375 (2014).
27. Prasanna SJ, Gopalakrishnan D, Shankar SR, Vasandan AB. Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS ONE 5(2), e9016 (2010).
28. Raicevic G, Najar M, Najimi M et al. Influence of inflammation on the immunological profile of adultderived human liver mesenchymal stromal cells and stellate cells. Cytotherapy 17(2), 174-185 (2015).
29. Nickel P, Bestard O, Volk HD, Reinke P. Diagnostic value of T-cell monitoring assays in kidney transplantation. Curr. Opin. Organ Transplant. 14(4), 426-431 (2009).
30. Hricik DE, Poggio ED, Woodside KJ et al. Effects of cellular sensitization and donor age on acute rejection and graft function after deceased-donor kidney transplantation. Transplantation 95(10), 1254-1258 (2013).
31. Andree H, Nickel P, Nasiadko C et al. Identification of dialysis patients with panel-reactive memory T cells before kidney transplantation using an allogeneic cell bank. J. Am. Soc. Nephrol. 17(2), 573-580 (2006).
32. Sundin M, Barrett AJ, Ringden O et al. HSCT recipients have specific tolerance to MSC but not to the MSC donor. J. Immunother. 32(7), 755-764 (2009).
33. Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat. Biotechnol. 32(3), 252-260 (2014).
34. Lee M, Jeong SY, Ha J et al. Low immunogenicity of allogeneic human umbilical cord blood-derived mesenchymal stem cells in vitro and in vivo. Biochem. Biophys. Res. Commun. 446(4), 983-989 (2014).
35. Martin-Fontecha A, Thomsen LL, Brett S et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat. Immunol. 5(12), 1260-1265 (2004).
36. Morandi B, Bougras G, Muller WA, Ferlazzo G, Munz C. NK cells of human secondary lymphoid tissues enhance T cell polarization via IFN-gamma secretion. Eur. J. Immunol. 36(9), 2394-2400 (2006).
37. Jiang XX, Zhang Y, Liu B et al. Human mesenchymal stem cells inhibit differentiation and function of monocytederived dendritic cells. Blood 105(10), 4120-4126 (2005).
38. Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J. Immunol. 177(4), 2080-2087 (2006).
39. Li YP, Paczesny S, Lauret E et al. Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the notch pathway. J. Immunol. 180(3), 1598-1608 (2008).
40. Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 113(26), 6576-6583 (2009).
41. Varol C, Landsman L, Fogg DK et al. Monocytes give rise to mucosal, but not splenic, conventional dendritic cells. J. Exp. Med. 204(1), 171-180 (2007).
42. Liu K, Victora GD, Schwickert TA et al. In vivo analysis of dendritic cell development and homeostasis. Science 324(5925), 392-397 (2009).
43. English K, Barry FP, Mahon BP. Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol. Lett. 115(1), 50-58 (2008).
44. Deng Y, Yi S, Wang G et al. Umbilical cord-derived mesenchymal stem cells instruct dendritic cells to acquire tolerogenic phenotypes through the IL-6-mediated upregulation of SOCS1. Stem Cells Dev. 23(17), 2080-2092 (2014).
45. Bassi EJ, De Almeida DC, Moraes-Vieira PM, Camara NO. Exploring the role of soluble factors associated with immune regulatory properties of mesenchymal stem cells. Stem Cell Rev. 8(2), 329-342 (2012).
46. Melief SM, Geutskens SB, Fibbe WE, Roelofs H. Multipotent stromal cells skew monocytes towards an anti-inflammatory interleukin-10-producing phenotype by production of interleukin-6. Haematologica 98(6), 888-895 (2013).
47. Yanez R, Oviedo A, Aldea M, Bueren JA, Lamana M. Prostaglandin E2 plays a key role in the immunosuppressive properties of adipose and bone marrow tissue-derived mesenchymal stromal cells. Exp. Cell Res. 316(19), 3109-3123 (2010).
48. Zhang B, Liu R, Shi D et al. Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. Blood 113(1), 46-57 (2009).
49. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NKcell proliferation. Blood 107(4), 1484-1490 (2006).
50. Hoogduijn MJ, Roemeling-Van Rhijn M, Korevaar SS, Engela AU, Weimar W, Baan CC. Immunological aspects of allogeneic and autologous mesenchymal stem cell therapies. Hum. Gene Ther. 22(12), 1587-1591 (2011).
51. Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 24(1), 74-85 (2006).
52. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2, 3-dioxygenase and prostaglandin E2. Blood 111(3), 1327-1333 (2008).
53. Chatterjee D, Tufa DM, Baehre H, Hass R, Schmidt RE, Jacobs R. Natural killer cells acquire CD73 expression upon exposure to mesenchymal stem cells. Blood 123(4), 594-595 (2014).
54. Selmani Z, Naji A, Zidi I et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 26(1), 212-222 (2008).
55. Manetti R, Gerosa F, Giudizi MG et al. Interleukin 12 induces stable priming for interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones. J. Exp. Med. 179(4), 1273-1283 (1994).
56. Di Nicola M, Carlo-Stella C, Magni M et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99(10), 3838-3843 (2002).
57. Cutler AJ, Limbani V, Girdlestone J, Navarrete CV. Umbilical cord-derived mesenchymal stromal cells modulate monocyte function to suppress T cell proliferation. J. Immunol. 185(11), 6617-6623 (2010).
58. Francois M, Romieu-Mourez R, Li M, Galipeau J. Human MSC suppression correlates with cytokine induction of indoleamine 2, 3-dioxygenase and bystander M2 macrophage differentiation. Mol. Ther. 20(1), 187-195 (2012).
59. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105(4), 1815-1822 (2005).
60. Choi EW, Shin IS, Lee HW et al. Transplantation of CTLA4Ig gene-Transduced adipose tissue-derived mesenchymal stem cells reduces inflammatory immune response and improves Th1/Th2 balance in experimental autoimmune thyroiditis. J. Gene Med. 13(1), 3-16 (2011).
61. Batten P, Sarathchandra P, Antoniw JW et al. Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: relevance to tissue engineering human heart valves. Tissue Eng. 12(8), 2263-2273 (2006).
62. Bai L, Lennon DP, Eaton V et al. Human bone marrowderived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 57(11), 1192-1203 (2009).
63. Tatara R, Ozaki K, Kikuchi Y et al. Mesenchymal stromal cells inhibit Th17 but not regulatory T-cell differentiation. Cytotherapy 13(6), 686-694 (2011).
64. Duffy MM, Pindjakova J, Hanley SA et al. Mesenchymal stem cell inhibition of T-helper 17 cell-differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor. Eur. J. Immunol. 41(10), 2840-2851 (2011).
65. Pianta S, Bonassi Signoroni P, Muradore I et al. Amniotic membrane mesenchymal cells-derived factors skew T cell polarization toward Treg and downregulate Th1 and Th17 cells subsets. Stem Cell Rev. doi:10.1007/s12015-014-9558-4. (2014) (Epub ahead of print)
66. Griffin MD, Ryan AE, Alagesan S, Lohan P, Treacy O, Ritter T. Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far? Immunol. Cell Biol. 91(1), 40-51 (2013).
67. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3-dioxygenase-mediated tryptophan degradation. Blood 103(12), 4619-4621 (2004).
68. Najar M, Raicevic G, Boufker HI et al. Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources. Cell Immunol. 264(2), 171-179 (2010).
69. Krampera M, Cosmi L, Angeli R et al. Role for interferongamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24(2), 386-398 (2006).
70. Lu L, Wang DD, Li X, Zeng XF, Sun LY. [Mechanism of umbilical cord mesenchymal stem cells in the up-regulation of regulatory T cells by transforming growth factor beta1 in systemic lupus erythematosus]. Zhonghua Yi Xue Za Zhi 93(13), 980-983 (2013).
71. Wang Y, Zhang A, Ye Z, Xie H, Zheng S. Bone marrowderived mesenchymal stem cells inhibit acute rejection of rat liver allografts in association with regulatory T-cell expansion. Transplant. Proc. 41(10), 4352-4356 (2009).
72. Kavanagh H, Mahon BP. Allogeneic mesenchymal stem cells prevent allergic airway inflammation by inducing murine regulatory T cells. Allergy 66(4), 523-531 (2011).
73. English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, Mahon BP. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin. Exp. Immunol. 156(1), 149-160 (2009).
74. Beggs KJ, Lyubimov A, Borneman JN et al. Immunologic consequences of multiple, high-dose administration of allogeneic mesenchymal stem cells to baboons. Cell Transplant. 15(8-9), 711-721 (2006).
75. Everly MJ, Terasaki PI. Monitoring and treating posttransplant human leukocyte antigen antibodies. Hum. Immunol. 70(8), 655-659 (2009).
76. Wood KJ, Goto R. Mechanisms of rejection: current perspectives. Transplantation 93(1), 1-10 (2012).
77. Tabera S, Perez-Simon JA, Diez-Campelo M et al. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. Haematologica 93(9), 1301-1309 (2008).
78. Franquesa M, Hoogduijn MJ, Bestard O, Grinyo JM. Immunomodulatory effect of mesenchymal stem cells on B cells. Front. Immunol. 3, 212 (2012).
79. Rasmusson I, Le Blanc K, Sundberg B, Ringden O. Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand. J. Immunol. 65(4), 336-343 (2007).
80. Traggiai E, Volpi S, Schena F et al. Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells 26(2), 562-569 (2008).
81. Rosado MM, Bernardo ME, Scarsella M et al. Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells Is mediated by T cells. Stem Cells Dev. 24(1), 93-103 (2014).
82. Franquesa M, Mensah FK, Huizinga R et al. Human adipose tissue-derived mesenchymal stem cells abrogate plasmablast formation and induce regulatory B cells independently of T helper cells. Stem Cells doi:10.1002/stem.188 (2014) (Epub ahead of print).